1. Home
  2. NAK vs MNKD Comparison

NAK vs MNKD Comparison

Compare NAK & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Northern Dynasty Minerals Ltd.

NAK

Northern Dynasty Minerals Ltd.

HOLD

Current Price

$1.81

Market Cap

1.2B

ML Signal

HOLD

Logo MannKind Corporation

MNKD

MannKind Corporation

HOLD

Current Price

$3.86

Market Cap

1.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NAK
MNKD
Founded
1983
1991
Country
Canada
United States
Employees
N/A
N/A
Industry
Precious Metals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.2B
IPO Year
2002
2004

Fundamental Metrics

Financial Performance
Metric
NAK
MNKD
Price
$1.81
$3.86
Analyst Decision
Strong Buy
Buy
Analyst Count
2
8
Target Price
$2.50
$8.69
AVG Volume (30 Days)
7.4M
5.3M
Earning Date
05-15-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$348,966,000.00
Revenue This Year
N/A
$35.81
Revenue Next Year
N/A
$11.89
P/E Ratio
N/A
N/A
Revenue Growth
N/A
22.23
52 Week Low
$0.73
$2.23
52 Week High
$2.98
$6.51

Technical Indicators

Market Signals
Indicator
NAK
MNKD
Relative Strength Index (RSI) 39.53 59.46
Support Level $1.35 $3.30
Resistance Level $2.31 $3.94
Average True Range (ATR) 0.17 0.18
MACD -0.03 -0.00
Stochastic Oscillator 8.33 70.07

Price Performance

Historical Comparison
NAK
MNKD

About NAK Northern Dynasty Minerals Ltd.

Northern Dynasty Minerals Ltd is a mineral exploration company. It has a single operating segment of acquisition, exploration, and development of mineral properties. Its core asset is the Pebble Project located in Alaska, USA. The Pebble project is seeking to develop a deposit of copper, gold, molybdenum, and silver into a modern mining operation.

About MNKD MannKind Corporation

MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.

Share on Social Networks: